Craig-Hallum Maintains Buy on Fennec Pharmaceuticals, Raises Price Target to $18
Portfolio Pulse from Benzinga Newsdesk
Craig-Hallum analyst Chase Knickerbocker maintains a Buy rating on Fennec Pharmaceuticals (NASDAQ:FENC) and raises the price target from $17 to $18.
March 18, 2024 | 7:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Craig-Hallum analyst Chase Knickerbocker maintains a Buy rating on Fennec Pharmaceuticals and raises the price target from $17 to $18.
The upgrade in the price target by a reputable analyst like Chase Knickerbocker suggests a strong confidence in Fennec Pharmaceuticals' future performance. This is likely to be viewed positively by the market, potentially leading to a short-term increase in FENC's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100